Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 2/20 | 0.51 |
| ▸ | BCL9 | O00512 | 1/20 | 0.49 |
| ▸ | CTNNB1 | P35222 | 1/20 | 0.49 |
| ▸ | HTR2A | P28223 | 1/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.45 |
| ▸ | PKM | P14618 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | PDK1 | Q15118 | 1/20 | 0.44 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.44 |
| ▸ | PDK3 | Q15120 | 1/20 | 0.44 |
| ▸ | PDK4 | Q16654 | 1/20 | 0.44 |
| ▸ | MGLL | Q99685 | 2/20 | 0.44 |
| ▸ | NR1H4 | Q96RI1 | 1/20 | 0.43 |
| ▸ | ELANE | P08246 | 1/20 | 0.43 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.43 |
| ▸ | PTPN7 | P35236 | 1/20 | 0.42 |
| ▸ | PTPN12 | Q05209 | 1/20 | 0.42 |
| ▸ | PTPN22 | Q9Y2R2 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1461897 | 0.84 | ELANE (0.60) | GAABCL9CTNNB1HTR2ASMN1; SMN2 | |
| SCHEMBL8144923 | 0.84 | GAA (0.47) | GAABCL9CTNNB1HTR2ASMN1; SMN2 | |
| SCHEMBL2721445 | 0.82 | GAA (0.54) | GAABCL9CTNNB1HTR2ASMN1; SMN2 | |
| SCHEMBL16407834 | 0.81 | GAA (0.50) | GAABCL9CTNNB1HTR2ASMN1; SMN2 | |
| SCHEMBL10140437 | 0.81 | GAA (0.50) | GAABCL9CTNNB1HTR2ASMN1; SMN2 | |
| SCHEMBL31488048 | 0.81 | BCL9 (0.51) | GAABCL9CTNNB1HTR2ASMN1; SMN2 | |
| SCHEMBL763093 | 0.81 | BCL9 (0.54) | GAABCL9CTNNB1HTR2ASMN1; SMN2 | |
| SCHEMBL5487025 | 0.79 | GAA (0.51) | GAABCL9CTNNB1HTR2ASMN1; SMN2 | |
| SCHEMBL6348996 | 0.79 | BCL9 (0.56) | GAABCL9CTNNB1HTR2ASMN1; SMN2 | |
| SCHEMBL7412943 | 0.79 | GAA (0.51) | GAABCL9CTNNB1HTR2ASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 52 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12441762-B2 | Hepatitis c virus NS3/4A protease inhibitors | UNIVERSITY OF MASSACHUSETTS (US) | 2025-10-14 | — | — | US | disclosed |
| WO-2025089370-A1 | COMPOUNDS AS CSF1R INHIBITORS | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2025-05-01 | — | — | WO | disclosed |
| US-20230099018-A1 | HEPATITIS C VIRUS NS3/4A PROTEASE INHIBITORS | UNIV MASSACHUSETTS (US) | 2023-03-30 | — | — | US | disclosed |
| US-11472778-B2 | Hepatitis C virus NS3/4A protease inhibitors | UNIVERSITY OF MASSACHUSETTS (US) | 2022-10-18 | — | — | US | disclosed |
| US-20220227806-A1 | HEPATITIS C VIRUS NS3/4A PROTEASE INHIBITORS | UNIV MASSACHUSETTS (US) | 2022-07-21 | — | — | US | disclosed |
| US-10745364-B2 | Tetrahydronaphthyridine, benzoxazine, aza-benzoxazine and related bicyclic compounds for inhibition of RORgamma activity and the treatment of disease | LYCERA CORPORATION (US) | 2020-08-18 | — | — | US | disclosed |
| EP-3661931-A1 | HETEROCYCLIC COMPOUND | Takeda Pharmaceutical Company Limited (JP) | 2020-06-10 | — | — | EP | disclosed |
| US-10435399-B2 | HDAC6 inhibitory heterocyclic compound | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2019-10-08 | — | — | US | disclosed |
| US-20190292159-A1 | TETRAHYDRONAPHTHYRIDINE, BENZOXAZINE, AZA-BENZOXAZINE AND RELATED BICYCLIC COMPOUNDS FOR INHIBITION OF RORgamma ACTIVITY AND THE TREATMENT OF DISEASE | MERCK SHARP & DOHME LLC | 2019-09-26 | — | — | US | disclosed |
| US-20190135799-A1 | HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2019-05-09 | — | — | US | disclosed |
| US-20110135604-A1 | ANTIVIRAL COMPOUNDS | GILEAD SCIENCES, INC. (US) | 2011-06-09 | — | — | US | disclosed |
| US-20110135604-A1 | ANTIVIRAL COMPOUNDS | GILEAD SCIENCES, INC. (US) | 2011-06-09 | — | — | US | disclosed |
| WO-2010111050-A1 | NOVEL AMINOPYRIDINE DERIVATIVES HAVING AURORA A SELECTIVE INHIBITORY ACTION | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2010-09-30 | — | — | WO | disclosed |
| WO-2010111057-A1 | NOVEL AMINOPYRIDINE DERIVATIVES HAVING AURORA A SELECTIVE INHIBITORY ACTION | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2010-09-30 | — | — | WO | disclosed |
| EP-2162432-A2 | ANTIVIRAL COMPOUNDS | Gilead Sciences, Inc. (US) | 2010-03-17 | — | — | EP | disclosed |
| US-20090186869-A1 | Antiviral compounds | GILEAD SCIENCES, INC. (US) | 2009-07-23 | — | — | US | disclosed |
| US-20090186869-A1 | Antiviral compounds | GILEAD SCIENCES, INC. (US) | 2009-07-23 | — | — | US | disclosed |
| US-20090186869-A1 | Antiviral compounds | GILEAD SCIENCES, INC. (US) | 2009-07-23 | — | — | US | disclosed |
| WO-2009005677-A2 | ANTIVIRAL COMPOUNDS | GILEAD SCIENCES, INC. (US) | 2009-01-08 | — | — | WO | disclosed |
| WO-2009005677-A2 | ANTIVIRAL COMPOUNDS | GILEAD SCIENCES, INC. (US) | 2009-01-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10745364-B2 | Tetrahydronaphthyridine, benzoxazine, aza-benzoxazine and related bicyclic compounds for inhibition of RORgamma activity and the treatment of disease | RORB, RORA, RORC | GAA 1111/4885BCL9 1571/4885CTNNB1 463/4885 |
| US-11472778-B2 | Hepatitis C virus NS3/4A protease inhibitors | HAVCR2, CTSC, DPP4 | GAA 294/4885BCL9 807/4885CTNNB1 1528/4885 |
| US-10435399-B2 | HDAC6 inhibitory heterocyclic compound | HDAC6, HDAC1, HDAC5 | GAA 191/4885BCL9 1972/4885CTNNB1 3526/4885 |
| US-20190135799-A1 | HETEROCYCLIC COMPOUND | HDAC1, HDAC5, HDAC6 | GAA 266/4885BCL9 1881/4885CTNNB1 3359/4885 |
| US-20090186869-A1 | Antiviral compounds | MAVS, EIF2AK2, ZC3HAV1 | GAA 151/4885BCL9 2453/4885CTNNB1 4473/4885 |
| US-12441762-B2 | Hepatitis c virus NS3/4A protease inhibitors | HAVCR2, CTSC, DPP4 | GAA 294/4885BCL9 807/4885CTNNB1 1528/4885 |
| US-20220227806-A1 | HEPATITIS C VIRUS NS3/4A PROTEASE INHIBITORS | HAVCR2, CTSC, DPP4 | GAA 294/4885BCL9 807/4885CTNNB1 1528/4885 |
| US-20110135604-A1 | ANTIVIRAL COMPOUNDS | MAVS, EIF2AK2, ZC3HAV1 | GAA 151/4885BCL9 2453/4885CTNNB1 4473/4885 |
| US-20190292159-A1 | TETRAHYDRONAPHTHYRIDINE, BENZOXAZINE, AZA-BENZOXAZINE AND RELATED BICYCLIC COMPOUNDS FOR INHIBITION OF RORgamma ACTIVITY AND THE TREATMENT OF DISEASE | RORB, RORA, RORC | GAA 1111/4885BCL9 1571/4885CTNNB1 463/4885 |
| US-20230099018-A1 | HEPATITIS C VIRUS NS3/4A PROTEASE INHIBITORS | HAVCR2, CTSC, DPP4 | GAA 294/4885BCL9 807/4885CTNNB1 1528/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.